Interpace Biosciences, Inc. (OTCMKTS:IDXG – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 14th, there was short interest totaling 91 shares, a decline of 80.7% from the July 30th total of 472 shares. Based on an average daily volume of 17,299 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.
Interpace Biosciences Price Performance
OTCMKTS IDXG traded down $0.01 during mid-day trading on Wednesday, hitting $1.42. The stock had a trading volume of 100 shares, compared to its average volume of 7,197. The firm’s 50 day moving average is $1.59 and its 200 day moving average is $1.75. The stock has a market capitalization of $6.29 million, a price-to-earnings ratio of 17.75 and a beta of 0.61. Interpace Biosciences has a twelve month low of $0.77 and a twelve month high of $2.40.
Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) last announced its earnings results on Monday, August 10th. The business services provider reported $0.01 earnings per share (EPS) for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%. The company had revenue of $9.13 million for the quarter.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
See Also
- Five stocks we like better than Interpace Biosciences
- HONA: The Spin-Off Story the Market Is Reading Wrong
- Quantum Computing Is Raising the Stakes for Cybersecurity: 5 Stocks to Watch
- 5 Stocks to Buy in September Before Wall Street Catches On
- PDD Beat Earnings—So Why Did the Stock Still Fall?
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
